Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
M Popovic,MG Sarngadharan,E Read,
and
RC Gallo
A cell system was developed for the reproducible detection of human T-lymphotropic retroviruses (HTLV family) from patients with the acquired immunodeficiency syndrome (AIDS) or with signs or symptoms that frequently precede AIDS (pre-AIDS). The cells are specific clones from a permissive human neoplastic T-cell line. Some of the clones permanently grow and continuously produce large amounts of virus after infection with cytopathic (HTLV-III) variants of these viruses. One cytopathic effect of HTLV-III in this system is the arrangement of multiple nuclei in a characteristic ring formation in giant cells of the infected T-cell population. These structures can be used as an indicator to detect HTLV-III in clinical specimens. This system opens the way to the routine detection of HTLV-III and related cytopathic variants of HTLV in patients with AIDS or pre-AIDS and in healthy carriers, and it provides large amounts of virus for detailed molecular and immunological analyses.
The editors suggest the following Related Resources on Science sites:
In Science Magazine
NEWS OF THE WEEK
Jon Cohen and Martin Enserink (10 October 2008) Science322 (5899), 174.
[DOI: 10.1126/science.322.5899.174] |Summary »|Full Text »|PDF »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm.
M. D. Simek, W. Rida, F. H. Priddy, P. Pung, E. Carrow, D. S. Laufer, J. K. Lehrman, M. Boaz, T. Tarragona-Fiol, G. Miiro, et al. (2009)
J. Virol.
83, 7337-7348
|Abstract »|Full Text »|PDF »
Albumin-conjugated C34 Peptide HIV-1 Fusion Inhibitor: EQUIPOTENT TO C34 AND T-20 IN VITRO WITH SUSTAINED ACTIVITY IN SCID-HU THY/LIV MICE.
C. A. Stoddart, G. Nault, S. A. Galkina, K. Thibaudeau, P. Bakis, N. Bousquet-Gagnon, M. Robitaille, M. Bellomo, V. Paradis, P. Liscourt, et al. (2008)
J. Biol. Chem.
283, 34045-34052
|Abstract »|Full Text »|PDF »
Activity of the Small Modified Amino Acid {alpha}-Hydroxy Glycineamide on In Vitro and In Vivo Human Immunodeficiency Virus Type 1 Capsid Assembly and Infectivity.
S. Abdurahman, A. Vegvari, M. Youssefi, M. Levi, S. Hoglund, E. Andersson, P. Horal, B. Svennerholm, J. Balzarini, and A. Vahlne (2008)
Antimicrob. Agents Chemother.
52, 3737-3744
|Abstract »|Full Text »|PDF »
Preclinical Evaluation of 1H-Benzylindole Derivatives as Novel Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors.
A. Hombrouck, B. Van Remoortel, M. Michiels, W. Noppe, F. Christ, A. Eneroth, B. L. Sahlberg, K. Benkestock, L. Vrang, N. G. Johansson, et al. (2008)
Antimicrob. Agents Chemother.
52, 2861-2869
|Abstract »|Full Text »|PDF »
Comparative Evaluation of Virus Transmission Inhibition by Dual-Acting Pyrimidinedione Microbicides Using the Microbicide Transmission and Sterilization Assay.
K. M. Watson, C. E. Buckheit, and R. W. Buckheit Jr. (2008)
Antimicrob. Agents Chemother.
52, 2787-2796
|Abstract »|Full Text »|PDF »
Mutations in Human Immunodeficiency Virus Type 1 Integrase Confer Resistance to the Naphthyridine L-870,810 and Cross-Resistance to the Clinical Trial Drug GS-9137.
A. Hombrouck, A. Voet, B. Van Remoortel, C. Desadeleer, M. De Maeyer, Z. Debyser, and M. Witvrouw (2008)
Antimicrob. Agents Chemother.
52, 2069-2078
|Abstract »|Full Text »|PDF »
Identification of functional microRNAs released through asymmetrical processing of HIV-1 TAR element.
D. L. Ouellet, I. Plante, P. Landry, C. Barat, M.-E. Janelle, L. Flamand, M. J. Tremblay, and P. Provost (2008)
Nucleic Acids Res.
36, 2353-2365
|Abstract »|Full Text »|PDF »
Active {beta}-Catenin Signaling Is an Inhibitory Pathway for Human Immunodeficiency Virus Replication in Peripheral Blood Mononuclear Cells.
A. Kumar, A. Zloza, R. T. Moon, J. Watts, A. R. Tenorio, and L. Al-Harthi (2008)
J. Virol.
82, 2813-2820
|Abstract »|Full Text »|PDF »
Comparative Evaluation of the Inhibitory Activities of a Series of Pyrimidinedione Congeners That Inhibit Human Immunodeficiency Virus Types 1 and 2.
R. W. Buckheit Jr., T. L. Hartman, K. M. Watson, S.-G. Chung, and E.-H. Cho (2008)
Antimicrob. Agents Chemother.
52, 225-236
|Abstract »|Full Text »|PDF »
In Vitro Antiviral Activity and Cross-Resistance Profile of PL-100, a Novel Protease Inhibitor of Human Immunodeficiency Virus Type 1.
S. Dandache, G. Sevigny, J. Yelle, B. R. Stranix, N. Parkin, J. M. Schapiro, M. A. Wainberg, and J. J. Wu (2007)
Antimicrob. Agents Chemother.
51, 4036-4043
|Abstract »|Full Text »|PDF »
Human Immunodeficiency Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenetic and Therapeutic Implications.
L. Buonaguro, M. L. Tornesello, and F. M. Buonaguro (2007)
J. Virol.
81, 10209-10219
|Full Text »|PDF »
Reconstruction of the Hepatitis C Virus Epidemic in the US Hemophilia Population, 1940-1990.
J. J. Goedert, B. E. Chen, L. Preiss, L. M. Aledort, P. S. Rosenberg, and for the Second Multicenter Hemophilia Cohort Study (2007)
Am. J. Epidemiol.
165, 1443-1453
|Abstract »|Full Text »|PDF »
Efficiency of Human Immunodeficiency Virus Type 1 Postentry Infection Processes: Evidence against Disproportionate Numbers of Defective Virions.
J. A. Thomas, D. E. Ott, and R. J. Gorelick (2007)
J. Virol.
81, 4367-4370
|Abstract »|Full Text »|PDF »
Characterization of a Replication-Competent, Integrase-Defective Human Immunodeficiency Virus (HIV)/Simian Virus 40 Chimera as a Powerful Tool for the Discovery and Validation of HIV Integrase Inhibitors.
D. Daelemans, R. Lu, E. De Clercq, and A. Engelman (2007)
J. Virol.
81, 4381-4385
|Abstract »|Full Text »|PDF »
Novel In Vivo Model for the Study of Human Immunodeficiency Virus Type 1 Transcription Inhibitors: Evaluation of New 6-Desfluoroquinolone Derivatives.
M. Stevens, M. Pollicita, C. Pannecouque, E. Verbeken, O. Tabarrini, V. Cecchetti, S. Aquaro, C. F. Perno, A. Fravolini, E. De Clercq, et al. (2007)
Antimicrob. Agents Chemother.
51, 1407-1413
|Abstract »|Full Text »|PDF »
Inhibition of Human Immunodeficiency Virus Envelope Glycoprotein- Mediated Single Cell Lysis by Low-Molecular-Weight Antagonists of Viral Entry.
N. Madani, A. M. Hubicki, A. L. Perdigoto, M. Springer, and J. Sodroski (2007)
J. Virol.
81, 532-538
|Abstract »|Full Text »|PDF »
Overexpression of the Lens Epithelium-Derived Growth Factor/p75 Integrase Binding Domain Inhibits Human Immunodeficiency Virus Replication.
J. De Rijck, L. Vandekerckhove, R. Gijsbers, A. Hombrouck, J. Hendrix, J. Vercammen, Y. Engelborghs, F. Christ, and Z. Debyser (2006)
J. Virol.
80, 11498-11509
|Abstract »|Full Text »|PDF »
HIV-1 coreceptor preference is distinct from target cell tropism: a dual-parameter nomenclature to define viral phenotypes.
Development of a human immunodeficiency virus vector-based, single-cycle assay for evaluation of anti-integrase compounds..
R. Bona, M. Andreotti, V. Buffa, P. Leone, C. M. Galluzzo, R. Amici, L. Palmisano, M. G. Mancini, Z. Michelini, R. Di Santo, et al. (2006)
Antimicrob. Agents Chemother.
50, 3407-3417
|Abstract »|Full Text »|PDF »
Comparison of Human Immunodeficiency Virus Type 1-Specific Inhibitory Activities in Saliva and Other Human Mucosal Fluids.
S. H. Kazmi, J. R. Naglik, S. P. Sweet, R. W. Evans, S. O'Shea, J. E. Banatvala, and S. J. Challacombe (2006)
Clin. Vaccine Immunol.
13, 1111-1118
|Abstract »|Full Text »|PDF »
In Vitro Microbicidal Activity of the Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) UC781 against NNRTI-Resistant Human Immunodeficiency Virus Type 1.
Replication-dependent fitness recovery of Human immunodeficiency virus 1 harbouring mutations of Asn17 of the nucleocapsid protein..
J. Tozser, S. Shulenin, M. R. Young, C. J. Briggs, and S. Oroszlan (2006)
J. Gen. Virol.
87, 961-965
|Abstract »|Full Text »|PDF »
Cashing in on Shame: How the Popular "Tradition vs. Modernity" Dualism Contributes to the "HIV/AIDS Crisis" in Africa.
H. Lauer (2006)
Review of Radical Political Economics
38, 90-138
|Abstract »|PDF »
The Synthetic Peptide Derived from the NH2-terminal Extracellular Region of an Orphan G Protein-coupled Receptor, GPR1, Preferentially Inhibits Infection of X4 HIV-1.
A. Jinno-Oue, N. Shimizu, Y. Soda, A. Tanaka, T. Ohtsuki, D. Kurosaki, Y. Suzuki, and H. Hoshino (2005)
J. Biol. Chem.
280, 30924-30934
|Abstract »|Full Text »|PDF »
An Exonic Splicing Silencer Downstream of the 3' Splice Site A2 Is Required for Efficient Human Immunodeficiency Virus Type 1 Replication.
What Caused the Epidemic of Pneumocystis Pneumonia in European Premature Infants in the Mid-20th Century?.
A. S. Goldman, L. R. Goldman, and D. A. Goldman (2005)
Pediatrics
115, e725-e736
|Abstract »|Full Text »|PDF »
Ex Vivo Modeling of Oral HIV Transmission in Human Palatine Tonsil.
D. M. Maher, Z.-Q. Zhang, T. W. Schacker, and P. J. Southern (2005)
J. Histochem. Cytochem.
53, 631-642
|Abstract »|Full Text »|PDF »
A Novel and Efficient Approach to Discriminate between Pre- and Post-Transcription HIV Inhibitors.
D. Daelemans, C. Pannecouque, G. N. Pavlakis, O. Tabarrini, and E. De Clercq (2005)
Mol. Pharmacol.
67, 1574-1580
|Abstract »|Full Text »|PDF »
TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells.
J.-P. Herbeuval, A. Boasso, J.-C. Grivel, A. W. Hardy, S. A. Anderson, M. J. Dolan, C. Chougnet, J. D. Lifson, and G. M. Shearer (2005)
Blood
105, 2458-2464
|Abstract »|Full Text »|PDF »
Anti-Vpr Activity of a Yeast Chaperone Protein.
Z. Benko, D. Liang, E. Agbottah, J. Hou, K. Chiu, M. Yu, S. Innis, P. Reed, W. Kabat, R. T. Elder, et al. (2004)
J. Virol.
78, 11016-11029
|Abstract »|Full Text »|PDF »
Persistent Infection with Primate Foamy Virus Type 1 Increases Human Immunodeficiency Virus Type 1 Cell Binding via a Bet-Independent Mechanism.
C. Schiffer, C.-H. Lecellier, A. Mannioui, N. Felix, E. Nelson, J. Lehmann-Che, M.-L. Giron, J. C. Gluckman, A. Saib, and B. Canque (2004)
J. Virol.
78, 11405-11410
|Abstract »|Full Text »|PDF »
A Nonneutralizing Anti-HIV-1 Antibody Turns into a Neutralizing Antibody When Expressed on the Surface of HIV-1-Susceptible Cells: A New Way to Fight HIV.
S.-J. Lee, L. Garza, J. Yao, A. L. Notkins, and P. Zhou (2004)
J. Immunol.
173, 4618-4626
|Abstract »|Full Text »|PDF »
DNA Vaccines against Human Immunodeficiency Virus Type 1 in the Past Decade.
M. Giri, K. E. Ugen, and D. B. Weiner (2004)
Clin. Microbiol. Rev.
17, 370-389
|Abstract »|Full Text »|PDF »
Orally Active Fusion Inhibitor of Respiratory Syncytial Virus.
C. Cianci, K.-L. Yu, K. Combrink, N. Sin, B. Pearce, A. Wang, R. Civiello, S. Voss, G. Luo, K. Kadow, et al. (2004)
Antimicrob. Agents Chemother.
48, 413-422
|Abstract »|Full Text »|PDF »
Development of Resistance against Diketo Derivatives of Human Immunodeficiency Virus Type 1 by Progressive Accumulation of Integrase Mutations.
V. Fikkert, B. Van Maele, J. Vercammen, A. Hantson, B. Van Remoortel, M. Michiels, C. Gurnari, C. Pannecouque, M. De Maeyer, Y. Engelborghs, et al. (2003)
J. Virol.
77, 11459-11470
|Abstract »|Full Text »|PDF »
Novel Human Immunodeficiency Virus (HIV) Inhibitors That Have a Dual Mode of Anti-HIV Action.
M. Stevens, C. Pannecouque, E. De Clercq, and J. Balzarini (2003)
Antimicrob. Agents Chemother.
47, 3109-3116
|Abstract »|Full Text »|PDF »
Impacts of Avidity and Specificity on the Antiviral Efficiency of HIV-1-Specific CTL.
O. O. Yang, P. T. N. Sarkis, A. Trocha, S. A. Kalams, R. P. Johnson, and B. D. Walker (2003)
J. Immunol.
171, 3718-3724
|Abstract »|Full Text »|PDF »
Inhibition of Human Immunodeficiency Virus by a New Class of Pyridine Oxide Derivatives.
M. Stevens, C. Pannecouque, E. De Clercq, and J. Balzarini (2003)
Antimicrob. Agents Chemother.
47, 2951-2957
|Abstract »|Full Text »|PDF »
Improved Protection of Rhesus Macaques against Intrarectal Simian Immunodeficiency Virus SIVmac251 Challenge by a Replication-Competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag Recombinant Priming/gp120 Boosting Regimen.
J. Zhao, J. Pinczewski, V. R. Gomez-Roman, D. Venzon, V. S. Kalyanaraman, P. D. Markham, K. Aldrich, M. Moake, D. C. Montefiori, Y. Lou, et al. (2003)
J. Virol.
77, 8354-8365
|Abstract »|Full Text »|PDF »
Human Cellular Nucleic Acid-Binding Protein Zn2+ Fingers Support Replication of Human Immunodeficiency Virus Type 1 When They Are Substituted in the Nucleocapsid Protein.
C. F. McGrath, J. S. Buckman, T. D. Gagliardi, W. J. Bosche, L. V. Coren, and R. J. Gorelick (2003)
J. Virol.
77, 8524-8531
|Abstract »|Full Text »|PDF »
Determinants of HIV-1 Mutational Escape From Cytotoxic T Lymphocytes.
O. O. Yang, P. T. N. Sarkis, A. Ali, J. D. Harlow, C. Brander, S. A. Kalams, and B. D. Walker (2003)
J. Exp. Med.
197, 1365-1375
|Abstract »|Full Text »|PDF »
Inhibition of Tat-mediated Transactivation and HIV-1 Replication by Human Anti-hCyclinT1 Intrabodies.
J. Bai, J. Sui, R. Y. Zhu, A. St. C. Tallarico, F. Gennari, D. Zhang, and W. A. Marasco (2003)
J. Biol. Chem.
278, 1433-1442
|Abstract »|Full Text »|PDF »
Actinomycin D Induces High-Level Resistance to Thymidine Analogs in Replication of Human Immunodeficiency Virus Type 1 by Interfering with Host Cell Thymidine Kinase Expression.
T. Imamichi, M. A. Murphy, J. W. Adelsberger, J. Yang, C. M. Watkins, S. C. Berg, M. W. Baseler, R. A. Lempicki, J. Guo, J. G. Levin, et al. (2002)
J. Virol.
77, 1011-1020
|Abstract »|Full Text »|PDF »
Productive Infection of Plasmacytoid Dendritic Cells with Human Immunodeficiency Virus Type 1 Is Triggered by CD40 Ligation.
L. Fong, M. Mengozzi, N. W. Abbey, B. G. Herndier, and E. G. Engleman (2002)
J. Virol.
76, 11033-11041
|Abstract »|Full Text »|PDF »
Characterization of a human immunodeficiency virus type 1 pre-integration complex in which the majority of the cDNA is resistant to DNase I digestion.
Antiretrovirus Activity of a Novel Class of Acyclic Pyrimidine Nucleoside Phosphonates.
J. Balzarini, C. Pannecouque, E. De Clercq, S. Aquaro, C.-F. Perno, H. Egberink, and A. Holy (2002)
Antimicrob. Agents Chemother.
46, 2185-2193
|Abstract »|Full Text »|PDF »
A Tight-Binding Mode of Inhibition Is Essential for Anti-Human Immunodeficiency Virus Type 1 Virucidal Activity of Nonnucleoside Reverse Transcriptase Inhibitors.
D. Motakis and M. A. Parniak (2002)
Antimicrob. Agents Chemother.
46, 1851-1856
|Abstract »|Full Text »|PDF »
Cytopathic Killing of Peripheral Blood CD4+ T Lymphocytes by Human Immunodeficiency Virus Type 1 Appears Necrotic rather than Apoptotic and Does Not Require env.
M. J. Lenardo, S. B. Angleman, V. Bounkeua, J. Dimas, M. G. Duvall, M. B. Graubard, F. Hornung, M. C. Selkirk, C. K. Speirs, C. Trageser, et al. (2002)
J. Virol.
76, 5082-5093
|Abstract »|Full Text »|PDF »
Mechanism of Human Immunodeficiency Virus-Induced Complement Expression in Astrocytes and Neurons.
C. Speth, T. Schabetsberger, I. Mohsenipour, G. Stockl, R. Wurzner, H. Stoiber, C. Lass-Florl, and M. P. Dierich (2002)
J. Virol.
76, 3179-3188
|Abstract »|Full Text »|PDF »
Nef-Mediated Resistance of Human Immunodeficiency Virus Type 1 to Antiviral Cytotoxic T Lymphocytes.
O. O. Yang, P. T. Nguyen, S. A. Kalams, T. Dorfman, H. G. Gottlinger, S. Stewart, I. S. Y. Chen, S. Threlkeld, and B. D. Walker (2002)
J. Virol.
76, 1626-1631
|Abstract »|Full Text »|PDF »
Oxidative Modifications of Kynostatin-272, a Potent Human Immunodeficiency Virus Type 1 Protease Inhibitor: Potential Mechanism for Altered Activity in Monocytes/Macrophages.
D. A. Davis, E. Read-Connole, K. Pearson, H. M. Fales, F. M. Newcomb, J. Moskovitz, and R. Yarchoan (2002)
Antimicrob. Agents Chemother.
46, 402-408
|Abstract »|Full Text »|PDF »
Induction of Rapid and Extensive beta -Chemokine Synthesis in Macrophages by Human Immunodeficiency Virus Type 1 and gp120, Independently of Their Coreceptor Phenotype.
Human Immunodeficiency Virus Type 1 IIIB Selected for Replication In Vivo Exhibits Increased Envelope Glycoproteins in Virions without Alteration in Coreceptor Usage: Separation of In Vivo Replication from Macrophage Tropism.
E. D. Miller, K. M. Duus, M. Townsend, Y. Yi, R. Collman, M. Reitz, and L. Su (2001)
J. Virol.
75, 8498-8506
|Abstract »|Full Text »|PDF »
Human Immunodeficiency Virus Type 1 Replication in the Absence of Integrase-Mediated DNA Recombination: Definition of Permissive and Nonpermissive T-Cell Lines.
Separation of Human Immunodeficiency Virus Type 1 Replication from nef-Mediated Pathogenesis in the Human Thymus.
K. M. Duus, E. D. Miller, J. A. Smith, G. I. Kovalev, and L. Su (2001)
J. Virol.
75, 3916-3924
|Abstract »|Full Text »
Human Immunodeficiency Virus Type 1 Induces Expression of Complement Factors in Human Astrocytes.
C. Speth, G. Stöckl, I. Mohsenipour, R. Würzner, H. Stoiber, C. Lass-Flörl, and M. P. Dierich (2001)
J. Virol.
75, 2604-2615
|Abstract »|Full Text »
Role for Human Immunodeficiency Virus Type 1 Tat Protein in Suppression of Viral Reverse Transcriptase Activity during Late Stages of Viral Replication.
M. Kameoka, L. Rong, M. Götte, C. Liang, R. S. Russell, and M. A. Wainberg (2001)
J. Virol.
75, 2675-2683
|Abstract »|Full Text »
GLI-2 Modulates Retroviral Gene Expression.
M. J. Smith, S. D. Gitlin, C. M. Browning, B. R. Lane, N. M. Clark, N. Shah, S. Rainier, and D. M. Markovitz (2001)
J. Virol.
75, 2301-2313
|Abstract »|Full Text »
Partial Activation and Induction of Apoptosis in CD4+ and CD8+ T Lymphocytes by Conformationally Authentic Noninfectious Human Immunodeficiency Virus Type 1.
M. T. Esser, J. W. Bess Jr., K. Suryanarayana, E. Chertova, D. Marti, M. Carrington, L. O. Arthur, and J. D. Lifson (2001)
J. Virol.
75, 1152-1164
|Abstract »|Full Text »
Polyanionic (i.e., Polysulfonate) Dendrimers Can Inhibit the Replication of Human Immunodeficiency Virus by Interfering with Both Virus Adsorption and Later Steps (Reverse Transcriptase/Integrase) in the Virus Replicative Cycle.
M. Witvrouw, V. Fikkert, W. Pluymers, B. Matthews, K. Mardel, D. Schols, J. Raff, Z. Debyser, E. De Clercq, G. Holan, et al. (2000)
Mol. Pharmacol.
58, 1100-1108
|Abstract »|Full Text »
Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors.
Z. Lai, I. Han, G. Zirzow, R. O. Brady, and J. Reiser (2000)
PNAS
97, 11297-11302
|Abstract »|Full Text »|PDF »
Primary macrophages infected by human immunodeficiency virus trigger CD95-mediated apoptosis of uninfected astrocytes.
S. Aquaro, S. Panti, M. C. Caroleo, E. Balestra, A. Cenci, F. Forbici, G. Ippolito, A. Mastino, R. Testi, V. Mollace, et al. (2000)
J. Leukoc. Biol.
68, 429-435
|Abstract »|Full Text »|PDF »
Viral Entry as the Primary Target for the Anti-HIV Activity of Chicoric Acid and Its Tetra-Acetyl Esters.
W. Pluymers, N. Neamati, C. Pannecouque, V. Fikkert, C. Marchand, T. R. Burke Jr., Y. Pommier, D. Schols, E. De Clercq, Z. Debyser, et al. (2000)
Mol. Pharmacol.
58, 641-648
|Abstract »|Full Text »
Performance of a Multiplex Qualitative PCR LCx Assay for Detection of Human Immunodeficiency Virus Type 1 (HIV-1) Group M Subtypes, Group O, and HIV-2.
K. Abravaya, C. Esping, R. Hoenle, J. Gorzowski, R. Perry, P. Kroeger, J. Robinson, and R. Flanders (2000)
J. Clin. Microbiol.
38, 716-723
|Abstract »|Full Text »
PCR-derived ssDNA Probes for Fluorescent In Situ Hybridization to HIV-1 RNA.
M. C. Knuchel, B. Graf, E. Schlaepfer, H. Kuster, M. Fischer, R. Weber, and R. W. Cone (2000)
J. Histochem. Cytochem.
48, 285-294
|Abstract »|Full Text »
Reversal of Human Immunodeficiency Virus Type 1 Protein-Induced Inhibition of Natural Killer Cell Activity by Alpha Interferon and Interleukin-2.
A Second Target for the Peptoid Tat/Transactivation Response Element Inhibitor CGP64222: Inhibition of Human Immunodeficiency Virus Replication by Blocking CXC-Chemokine Receptor 4-Mediated Virus Entry.
D. Daelemans, D. Schols, M. Witvrouw, C. Pannecouque, S. Hatse, S. van Dooren, F. Hamy, T. Klimkait, E. de Clercq, and A.-M. VanDamme (2000)
Mol. Pharmacol.
57, 116-124
|Abstract »|Full Text »
Determinants of CD4 Independence for a Human Immunodeficiency Virus Type 1 Variant Map outside Regions Required for Coreceptor Specificity.
C. C. LaBranche, T. L. Hoffman, J. Romano, B. S. Haggarty, T. G. Edwards, T. J. Matthews, R. W. Doms, and J. A. Hoxie (1999)
J. Virol.
73, 10310-10319
|Abstract »|Full Text »
Pseudotyping human immunodeficiency virus type 1 by vesicular stomatitis virus G protein does not reduce the cell-dependent requirement of Vif for optimal infectivity: functional difference between Vif and Nef.
H. Akari, T. Uchiyama, T. Fukumori, S. Iida, A. H. Koyama, and A. Adachi (1999)
J. Gen. Virol.
80, 2945-2949
|Abstract »|Full Text »
Anti-Kaposi's Sarcoma and Antiangiogenic Activities of Sulfated Dextrins.
M. Thornton, L. Barkley, J. C. Mason, and S. Shaunak (1999)
Antimicrob. Agents Chemother.
43, 2528-2533
|Abstract »|Full Text »
Primary Human Immunodeficiency Virus Type 2 (HIV-2) Isolates Infect CD4-Negative Cells via CCR5 and CXCR4: Comparison with HIV-1 and Simian Immunodeficiency Virus and Relevance to Cell Tropism In Vivo.
J. D. Reeves, S. Hibbitts, G. Simmons, A. McKnight, J. M. Azevedo-Pereira, J. Moniz-Pereira, and P. R. Clapham (1999)
J. Virol.
73, 7795-7804
|Abstract »|Full Text »
Natural experimental models: The global search for biomedical paradigms among traditional, modernizing, and modern populations.
R. M. Garruto, M. A. Little, G. D. James, and D. E. Brown (1999)
PNAS
96, 10536-10543
|Abstract »|Full Text »|PDF »
Multiplex detection of four pathogenic retroviruses using molecular beacons.
J. A. M. Vet, A. R. Majithia, S. A. E. Marras, S. Tyagi, S. Dube, B. J. Poiesz, and F. R. Kramer (1999)
PNAS
96, 6394-6399
|Abstract »|Full Text »|PDF »
Evaluation of a Rapid Immunochromatographic Test for Detection of Antibodies to Human Immunodeficiency Virus.
H. Arai, B. Petchclai, K. Khupulsup, T. Kurimura, and K. Takeda (1999)
J. Clin. Microbiol.
37, 367-370
|Abstract »|Full Text »
CD4+ T-Lymphocyte Depletion in Human Lymphoid Tissue Ex Vivo Is Not Induced by Noninfectious Human Immunodeficiency Virus Type 1 Virions.
A. W. Sylwester, J.-C. Grivel, W. Fitzgerald, J. L. Rossio, J. D. Lifson, and L. B. Margolis (1998)
J. Virol.
72, 9345-9347
|Abstract »|Full Text »|PDF »
Selective Inhibition of HIV-1 Reverse Transcriptase by an Antiviral Inhibitor, (R)-9-(2-Phosphonylmethoxypropyl)adenine.
Chronically HIV-1-Infected Monocytic Cells Induce Apoptosis in Cocultured T Cells.
H. Chen, Y. K. Yip, I. George, M. Tyorkin, E. Salik, and K. Sperber (1998)
J. Immunol.
161, 4257-4267
|Abstract »|Full Text »|PDF »
Common Themes of Antibody Maturation to Simian Immunodeficiency Virus, Simian-Human Immunodeficiency Virus, and Human Immunodeficiency Virus Type 1 Infections.
K. S. Cole, M. Murphey-Corb, O. Narayan, S. V. Joag, G. M. Shaw, and R. C. Montelaro (1998)
J. Virol.
72, 7852-7859
|Abstract »|Full Text »|PDF »
Dissociation of the CD4 and CXCR4 Binding Properties of Human Immunodeficiency Virus Type 1 gp120 by Deletion of the First Putative Alpha-Helical Conserved Structure.
D. Misse, M. Cerutti, I. Schmidt, A. Jansen, G. Devauchelle, F. Jansen, and F. Veas (1998)
J. Virol.
72, 7280-7288
|Abstract »|Full Text »|PDF »
Continued Utilization of CCR5 Coreceptor by a Newly Derived T-Cell Line-Adapted Isolate of Human Immunodeficiency Virus Type 1.
K. E. Follis, M. Trahey, R. A. LaCasse, and J. H. Nunberg (1998)
J. Virol.
72, 7603-7608
|Abstract »|Full Text »|PDF »
The leukotriene B4 receptor functions as a novel type of coreceptor mediating entry of primary HIV-1 isolates into CD4-positive cells.
C. Owman, A. Garzino-Demo, F. Cocchi, M. Popovic, A. Sabirsh, and R. C. Gallo (1998)
PNAS
95, 9530-9534
|Abstract »|Full Text »|PDF »
Determinants of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Activation by Soluble CD4 and Monoclonal Antibodies.
N. Sullivan, Y. Sun, J. Binley, J. Lee, C. F. Barbas III, P. W. H. I. Parren, D. R. Burton, and J. Sodroski (1998)
J. Virol.
72, 6332-6338
|Abstract »|Full Text »|PDF »
Human Immunodeficiency Virus Type 1 Replication Is Modulated by Host Cyclophilin A Expression Levels.
CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization.
N. Sullivan, Y. Sun, Q. Sattentau, M. Thali, D. Wu, G. Denisova, J. Gershoni, J. Robinson, J. Moore, and J. Sodroski (1998)
J. Virol.
72, 4694-4703
|Abstract »|Full Text »|PDF »
Novel Inhibitory Effects of gamma -Glutamylcysteine Ethyl Ester against Human Immunodeficiency Virus Type 1 Production and Propagation.
S. Kubota, S. Shetty, H. Zhang, S. Kitahara, and R. J. Pomerantz (1998)
Antimicrob. Agents Chemother.
42, 1200-1206
|Abstract »|Full Text »
Characterization of V3 Loop-Pseudomonas Exotoxin Chimeras. CANDIDATE VACCINES FOR HUMAN IMMUNODEFICIENCY VIRUS-1.
D. J. FitzGerald, C. M. Fryling, M. L. McKee, J. C. Vennari, T. Wrin, M. E. M. Cromwell, A. L. Daugherty, and R. J. Mrsny (1998)
J. Biol. Chem.
273, 9951-9958
|Abstract »|Full Text »|PDF »
Cleavage of Human Immunodeficiency Virus Type 1 Proteinase from the N-Terminally Adjacent p6* Protein Is Essential for Efficient Gag Polyprotein Processing and Viral Infectivity.
The Lipophosphoglycan of Leishmania donovani Up-Regulates HIV-1 Transcription in T Cells Through the Nuclear Factor-{kappa}B Elements.
R. Bernier, B. Barbeau, M. J. Tremblay, and M. Olivier (1998)
J. Immunol.
160, 2881-2888
|Abstract »|Full Text »|PDF »
1,1,3-Trioxo-2H,4H-Thieno[3,4-e][1,2,4]Thiadiazine (TTD) Derivatives: a New Class of Nonnucleoside Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Inhibitors with Anti-HIV-1 Activity.
M. Witvrouw, M. E. Arranz, C. Pannecouque, R. Declercq, H. Jonckheere, J.-C. Schmit, A.-M. Vandamme, J. A. Diaz, S. T. Ingate, J. Desmyter, et al. (1998)
Antimicrob. Agents Chemother.
42, 618-623
|Abstract »|Full Text »
Nucleocapsid and Matrix Protein Contributions to Selective Human Immunodeficiency Virus Type 1 Genomic RNA Packaging.
Evolution of a Simian Immunodeficiency Virus Pathogen.
P. Edmonson, M. Murphey-Corb, L. N. Martin, C. Delahunty, J. Heeney, H. Kornfeld, P. R. Donahue, G. H. Learn, L. Hood, and J. I. Mullins (1998)
J. Virol.
72, 405-414
|Abstract »|Full Text »|PDF »
Spontaneous Mutations in the env Gene of the Human Immunodeficiency Virus Type 1 NDK Isolate Are Associated with a CD4-Independent Entry Phenotype.
J. Dumonceaux, S. Nisole, C. Chanel, L. Quivet, A. Amara, P. Briand, and U. Hazan (1998)
J. Virol.
72, 512-519
|Abstract »|Full Text »|PDF »
Mutations in HIV reverse transcriptase which alter RNase H activity and decrease strand transfer efficiency are suppressed by HIV nucleocapsid protein.
C. E. Cameron, M. Ghosh, S. F. J. Le Grice, and S. J. Benkovic (1997)
PNAS
94, 6700-6705
|Abstract »|Full Text »|PDF »
The Human Immunodeficiency Virus Type 1 (HIV-1) Vpu Protein Interferes with an Early Step in the Biosynthesis of Major Histocompatibility Complex (MHC) Class I Molecules.
T. Kerkau, I. Bacik, J. R. Bennink, J. W. Yewdell, T. Hunig, A. Schimpl, and U. Schubert (1997)
J. Exp. Med.
185, 1295-1306
|Abstract »|Full Text »|PDF »
Increased Uptake and Accumulation of Vitamin C in Human Immunodeficiency Virus 1-infected Hematopoietic Cell Lines.
C. I. Rivas, J. C. Vera, V. H. Guaiquil, F. V. Velasquez, O. A. Borquez-Ojeda, J. G. Carcamo, I. I. Concha, and D. W. Golde (1997)
J. Biol. Chem.
272, 5814-5820
|Abstract »|Full Text »|PDF »